BCDA vs ANIK

For growth investors, Anika Therapeutics, Inc.

(ANIK) is the stronger pick with -5. 9% revenue growth year-over-year, versus -87. 8% for BioCardia, Inc. (BCDA). Analysts rate Anika Therapeutics, Inc. (ANIK) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Anika Therapeutics, Inc.

(ANIK) delivered a total return of -63. 9%, compared to -99. 3% for BioCardia, Inc. (BCDA). Over 10 years, the gap is even starker: ANIK returned -65. 9% versus BCDA's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioCardia, Inc.

(BCDA) is the lower-risk stock at 1. 14β versus Anika Therapeutics, Inc. 's 1. 14β — meaning ANIK is approximately 0% more volatile than BCDA relative to the S&P 500. On balance sheet safety, Anika Therapeutics, Inc. (ANIK) carries a lower debt/equity ratio of 17% versus 114% for BioCardia, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Anika Therapeutics, Inc.

(ANIK) is pulling ahead at -5. 9% versus -87. 8% for BioCardia, Inc. (BCDA). On earnings-per-share growth, the picture is similar: Anika Therapeutics, Inc. grew EPS 80. 2% year-over-year, compared to 64. 6% for BioCardia, Inc.. Over a 3-year CAGR, ANIK leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Anika Therapeutics, Inc.

(ANIK) is the more profitable company, earning -9. 6% net margin versus -137. 0% for BioCardia, Inc. — meaning it keeps -9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIK leads at -9. 8% versus -137. 9% for BCDA. At the gross margin level — before operating expenses — ANIK leads at 56. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Anika Therapeutics, Inc.

(ANIK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 14)). Both have compounded well over 10 years (ANIK: -65. 9%, BCDA: -99. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.